Literature DB >> 16485347

COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.

Jane A Mitchell1, Timothy D Warner.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the formation of prostanoids by the enzyme cyclooxygenase (COX). Work in the past 15 years has shown that COX exists in two forms: COX1, which is largely associated with physiological functions, and COX2, which is largely associated with pathological functions. Heated debate followed the introduction of selective COX2 inhibitors around 5 years ago: do these drugs offer any advantages over the traditional NSAIDs theywere meant to replace, particularly in regard to gastrointestinal and cardiovascular side effects? Here we discuss the evidence and the latest recommendations for the use of selective inhibitors of COX2 as well as the traditional NSAIDs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485347     DOI: 10.1038/nrd1929

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  81 in total

1.  Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells.

Authors:  Qi Liu; Yutao Xi; Toya Terry; Shui-Ping So; Anita Mohite; Jia Zhang; Geru Wu; Xiaobing Liu; Jie Cheng; Ke-He Ruan; James T Willerson; Richard A F Dixon
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

Review 2.  The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.

Authors:  J A Cairns
Journal:  Can J Cardiol       Date:  2007-02       Impact factor: 5.223

Review 3.  Building a better aspirin: gaseous solutions to a century-old problem.

Authors:  J L Wallace
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

Review 4.  The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis.

Authors:  Carla R Scanzello; Neal K Moskowitz; Allan Gibofsky
Journal:  Curr Pain Headache Rep       Date:  2007-12

5.  COX-2 inhibitor reduces skeletal muscle hypertrophy in mice.

Authors:  Margaret L Novak; William Billich; Sierra M Smith; Kunal B Sukhija; Thomas J McLoughlin; Troy A Hornberger; Timothy J Koh
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-28       Impact factor: 3.619

6.  Brain-derived neurotrophic factor stimulates production of prostacyclin in cerebral arteries.

Authors:  Anantha Vijay R Santhanam; Leslie A Smith; Zvonimir S Katusic
Journal:  Stroke       Date:  2009-12-17       Impact factor: 7.914

Review 7.  Signaling cascades as drug targets in model and pathogenic fungi.

Authors:  Robert J Bastidas; Jennifer L Reedy; Helena Morales-Johansson; Joseph Heitman; Maria E Cardenas
Journal:  Curr Opin Investig Drugs       Date:  2008-08

Review 8.  Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition.

Authors:  May Hamza; Raymond A Dionne
Journal:  Curr Mol Pharmacol       Date:  2009-01       Impact factor: 3.339

9.  Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway.

Authors:  Jian Zhang; Ting Lei; Xiaodong Chen; Yin Peng; Huan Long; Lei Zhou; Jianfeng Huang; Zhilong Chen; Qinqiang Long; Zaiqing Yang
Journal:  Inflammation       Date:  2010-02       Impact factor: 4.092

10.  Celecoxib-induced change in atrial electrophysiologic substrate in arthritis patients.

Authors:  Katerina Pizzuto; Henry L Averns; Adrian Baranchuk; Hoshiar Abdollah; Kevin A Michael; Christopher Simpson; Damian P Redfearn
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-24       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.